Journal of Antimicrobial Chemotherapy (2000) 45, 483-488
© 2000 The British Society for Antimicrobial Chemotherapy
Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa
a Infectious Disease Section, Stratton VA Medical Center, 113 Holland Avenue; b Albany Medical College, Albany, NY 12208, USA
Intracellular bacteria often cause relapsing and refractory infections. However, these infections can be treated effectively with antibiotics such as ofloxacin which penetrate into the cells containing bacteria. As levofloxacin, the levorotatory isomer of ofloxacin, has enhanced antibacterial activity, we tested the levofloxacin concentration in human monocytes and the effects of intracellular levofloxacin on monocyte killing of Staphylococcus aureus strain ATCC 29213 and Pseudomonas aeruginosa strain PA1348A. Human monocytes were incubated with levofloxacin at various pH values and temperatures. Following incubation, the monocytes were separated from incubation media, and intracellular (C) and extracellular (E) levofloxacin concentrations were determined. Mean C/E ratios after 15 min of incubation with 6 and 12 mg/L levofloxacin at pH 7.4 were 6.4 and 7.1, respectively. C/E ratios were similar at pH 7.4 and 8.0, but decreased at lower pH values. To study the effects of levofloxacin on intracellular killing of S. aureus and P. aeruginosa, opsonized bacteria were added to monolayers of monocytes. Following phagocytosis, monocytes were incubated with various concentrations of levofloxacin, ciprofloxacin and rifampicin, alone or in combination. Levofloxacin (2.5 and 4 mg/L) significantly reduced the survival of cell-associated S. aureus and was more effective than ciprofloxacin at similar concentrations (P < 0.01). Enhanced killing of cell-associated P. aeruginosa by levofloxacin (0.5 and 1.0 mg/L) was also observed. Activities of levofloxacin and ciprofloxacin against cell-associated P. aeruginosa were similar. Addition of rifampicin did not augment the bactericidal activity of levofloxacin. Since levofloxacin is concentrated in human monocytes and increases their bactericidal activity against intracellular bacteria, it should be considered for treatment of infections caused by susceptible intracellular bacteria.
* Corresponding author. Tel: +1-518-462-3311 ext. 3080; Fax: +1-518-462-3350; E-mail: smith.raymond{at}albany.va.gov
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Perlroth, M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature Arch Intern Med, April 28, 2008; 168(8): 805 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Baltch, L. H. Bopp, R. P. Smith, P. B. Michelsen, and W. J. Ritz Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes J. Antimicrob. Chemother., July 1, 2005; 56(1): 104 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Smith, A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2081 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gottenbos, F. Klatter, H. C. Van Der Mei, H. J. Busscher, and P. Nieuwenhuis Late Hematogenous Infection of Subcutaneous Implants in Rats Clin. Vaccine Immunol., September 1, 2001; 8(5): 980 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Edelstein, T. Shinzato, E. Doyle, and M. A. C. Edelstein In Vitro Activity of Gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and Its Pharmacokinetics in Guinea Pigs with L. pneumophila Pneumonia Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2204 - 2209. [Abstract] [Full Text] [PDF]
|
|